Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Trial of Stereotactic Adaptive Radiation Therapy for Borderline Resectable/Locally Advanced Pancreatic Cancer: An Individualized Approach to Minimizing Gastrointestinal Toxicity (ARTIA-Pancreas)

NCT05764720 is registered in ClinicalTrials.gov with Varian, a Siemens Healthineers Company as lead sponsor.

NCT NCT05764720
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05764720 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Trial of Stereotactic Adaptive Radiation Therapy for Borderline Resectable/Locally Advanced Pancreatic Cancer: An Individualized Approach to Minimizing Gastrointestinal Toxicity (ARTIA-Pancreas)
Lead sponsor
Varian, a Siemens Healthineers Company
Phase
Not applicable
Overall status
Recruiting
Start date
May 14, 2023
Completion date
March 15, 2030
Enrollment
134 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer